Clinical Trial Detail

NCT ID NCT02268253
Title Tagraxofusp (SL-401) in Patients With CMML or MF
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Stemline Therapeutics, Inc.
Indications

myelofibrosis

chronic myelomonocytic leukemia

Therapies

tagraxofusp-erzs

Age Groups: adult senior

Additional content available in CKB BOOST